Overview of the Safety Profile of CAR-T Therapy

EP: 1.Rosie’s Journey with R/R MM

Now Viewing

EP: 2.Overview of the Safety Profile of CAR-T Therapy

EP: 3.Clinical Management of Cytokine Release Syndrome in CAR-T Therapy

EP: 4.Addressing Neurologic Toxicities in CAR-T Therapy: Monitoring, Management, and Patient Communication

EP: 5.Strategies for Managing Cytopenias and Infection Prophylaxis with CAR-T Therapy

EP: 6.Jackson’s Journey with High Risk R/R MM

EP: 7.Approach to Long-Term Management of CAR-T MM Patients

EP: 8.Importance of Multidisciplinary Approach in Care of CAR-T MM Patients

EP: 9.Real World Experience of CAR-T in MM Patients

EP: 10.Empowering Community Oncologists in the Era of CAR-T Therapy

Video content above is prompted by the following:

• Could you start by giving an overview of the safety profile of CAR-T therapies for multiple myeloma?
• In your experience, what are the most common and impactful adverse events linked to ide-cel and cilta-cel?
• How does this align with the safety data from the KarMMa and CARTITUDE studies?
• How do the safety profiles of ide-cel and cilta-cel compare, and how do they stack up against other CAR-T therapies?
• In what ways do these safety differences impact your choice of CAR-T product for different patient demographics?